1. Home
  2. NIXX vs EQ Comparison

NIXX vs EQ Comparison

Compare NIXX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIXX
  • EQ
  • Stock Information
  • Founded
  • NIXX 2010
  • EQ 2017
  • Country
  • NIXX United States
  • EQ United States
  • Employees
  • NIXX N/A
  • EQ N/A
  • Industry
  • NIXX
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • NIXX
  • EQ Health Care
  • Exchange
  • NIXX NYSE
  • EQ Nasdaq
  • Market Cap
  • NIXX 33.3M
  • EQ 39.0M
  • IPO Year
  • NIXX N/A
  • EQ 2018
  • Fundamental
  • Price
  • NIXX $2.59
  • EQ $0.71
  • Analyst Decision
  • NIXX
  • EQ Buy
  • Analyst Count
  • NIXX 0
  • EQ 2
  • Target Price
  • NIXX N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • NIXX 516.7K
  • EQ 311.1K
  • Earning Date
  • NIXX 11-22-2024
  • EQ 11-13-2024
  • Dividend Yield
  • NIXX N/A
  • EQ N/A
  • EPS Growth
  • NIXX N/A
  • EQ N/A
  • EPS
  • NIXX N/A
  • EQ N/A
  • Revenue
  • NIXX $716,528.00
  • EQ $45,914,000.00
  • Revenue This Year
  • NIXX N/A
  • EQ N/A
  • Revenue Next Year
  • NIXX N/A
  • EQ N/A
  • P/E Ratio
  • NIXX N/A
  • EQ N/A
  • Revenue Growth
  • NIXX N/A
  • EQ 7.70
  • 52 Week Low
  • NIXX $1.12
  • EQ $0.48
  • 52 Week High
  • NIXX $8.50
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • NIXX N/A
  • EQ 39.09
  • Support Level
  • NIXX N/A
  • EQ $0.68
  • Resistance Level
  • NIXX N/A
  • EQ $0.89
  • Average True Range (ATR)
  • NIXX 0.00
  • EQ 0.11
  • MACD
  • NIXX 0.00
  • EQ -0.03
  • Stochastic Oscillator
  • NIXX 0.00
  • EQ 5.49

About NIXX NIXXY INC

Nixxy Inc formerly Recruiter.Com Group Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 28,000 small and independent recruiters utilize a web platform, complete with AI-driven job matching, to recruit talent faster. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: